drugset / Trial / NCT03748173

Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04

NCT03748173 ↗

Phase 1 Terminated 13 enrolled ONY
RandomizedParallel-groupOpen-labelTreatment

Summary

Delivery of aerosolized Infasurf to bronchiolitis patients with who are not on assisted ventilation can provide sufficient delivery of Infasurf to small airways to improve ventilation and thereby shorten the duration of the respiratory illness.

Timeline

Start
2019-01-12
Primary completion
2020-10-02
Completion
2020-10-21

Outcome

Outcome not reported

Stopped: “slowdown due to covid”

Drugs

EvaluationDrugModalityDoseRoute
Subject Calfactant Protein / enzyme biologic 6 unknown Inhaled

Indications